A-Level students pick Cambridge brains

01 Jun 2015

Is drug addiction hereditary? Why do emotions dominate our earliest memories? Are robots a threat to humanity? These were just some of the thorny questions posed by A-Level students to Cambridge neuroscientists at a recent outreach event organised with the David Ross Educational Trust.

Read More
Modafinil

Record seizure of smart drugs including one untested in humans shows growing market

03 Nov 2014

Last month, the Medicines and Healthcare products Regulatory Agency announced the UK’s biggest ever single seizure of smart drugs, also known as cognitive enhancers. With over 20,000 units, of 13 different types of cognitive enhancement medicines, the seizure represents an approximate value of £200,000. Here, Professor Barbara Sahakian from the Department of Psychiatry discusses the implications. This article first appeared on The Conversation website on 31 October 2014.

Read More
Brain lobes

AstraZeneca and University of Cambridge strengthen long-standing partnership

16 Oct 2014

AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.

Read More

NICE approves MS drug developed by University of Cambridge researchers

28 May 2014

A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.

Read More